| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
© 2026 Aquestive Therapeutics, Inc. Disclaimer 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking sta... |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri... |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Warren, N.J., November 3, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, t... |
| 19 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
150023820.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. (As of October 1516[●], 20242026) ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for th... |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDU... |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal... |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotech... |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri... |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
H.C. Wainwright 28th Annual Global Investment Conference September 14, 2026 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Warren, N.J., August 11, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and de... |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film • Human factors and clinical study results support planned resubmission of An... |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
(a) Aquestive Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2026. |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more
Warren, N.J., May 13, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and deliv... |
| 30 Mar 2026 |
8-K: Regulation FD Disclosure
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film • Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026 • Received clarifying feedback from the FDA on pharmacok... |
| 20 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer • Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and ... |
| 04 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Warren, N.J., March 4, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and deli... |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
Advancing medicines. Solving problems. Improving lives. September 2024 Corporate Presentation February 2026 |
| 02 Feb 2026 |
8-K: Regulation FD Disclosure
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™ Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 ... |
| 09 Jan 2026 |
8-K: Other Events
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no fin... |
| 06 Nov 2025 |
8-K: Regulation FD Disclosure
Advancing medicines. Solving problems. Improving lives. September 2024 Third Quarter 2025 Earnings Supplemental Materials November 6, 2025 |
Loading...